{
  "success": true,
  "pagesUsed": [
    2,
    4,
    10,
    12,
    15,
    17,
    20,
    25,
    27,
    29,
    32,
    37,
    39,
    40,
    41,
    42,
    57
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "scheduling": {
    "timings": [
      {
        "id": "timing_1",
        "name": "End of Study Visit",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 54,
        "relativeTo": "First Dose",
        "windowLower": -2,
        "windowUpper": 2
      },
      {
        "id": "timing_2",
        "name": "Zinc Washout Period",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 21,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_3",
        "name": "Chelator Therapy Discontinuation",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_4",
        "name": "Enrollment and Registration",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_5",
        "name": "Run-in Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": -7,
        "relativeTo": "First Dose",
        "windowUpper": -1
      },
      {
        "id": "timing_6",
        "name": "CRU Admission Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": -8,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_7",
        "name": "CRU Discharge Period 1",
        "type": "At",
        "unit": "days",
        "instanceType": "Timing",
        "value": 9,
        "relativeTo": "First Dose"
      },
      {
        "id": "timing_8",
        "name": "CRU Re-admission Period 2",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 22,
        "relativeTo": "First Dose",
        "windowUpper": 23
      },
      {
        "id": "timing_9",
        "name": "15 mg/day Dosing Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 1,
        "relativeTo": "First Dose",
        "windowUpper": 28
      },
      {
        "id": "timing_10",
        "name": "30 mg/day Dosing Period",
        "type": "Between",
        "unit": "days",
        "instanceType": "Timing",
        "value": 29,
        "relativeTo": "First Dose",
        "windowUpper": 39
      },
      {
        "id": "timing_11",
        "name": "Experimental Therapy Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 90,
        "relativeTo": "Screening"
      },
      {
        "id": "timing_12",
        "name": "Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 14
      },
      {
        "id": "timing_13",
        "name": "Non-Prescription Medication Washout",
        "type": "Before",
        "unit": "days",
        "instanceType": "Timing",
        "value": 7
      },
      {
        "id": "timing_14",
        "name": "Alcohol Abstinence",
        "type": "Within",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 48,
        "relativeTo": "First Dose",
        "windowLower": -48,
        "windowUpper": 0
      },
      {
        "id": "timing_15",
        "name": "Pregnancy Testing Frequency",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 4,
        "relativeTo": "Previous Visit"
      },
      {
        "id": "timing_16",
        "name": "Outpatient Dosing Window",
        "type": "At",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 0,
        "windowLower": -1,
        "windowUpper": 1
      },
      {
        "id": "timing_17",
        "name": "Pre-dose Fasting",
        "type": "Before",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 10
      },
      {
        "id": "timing_18",
        "name": "Post-dose Meal Delay",
        "type": "After",
        "unit": "hours",
        "instanceType": "Timing",
        "value": 2
      },
      {
        "id": "timing_19",
        "name": "Safety Lab Monitoring Interval",
        "type": "At",
        "unit": "weeks",
        "instanceType": "Timing",
        "value": 1
      }
    ],
    "conditions": [
      {
        "id": "cond_1",
        "name": "Elevated Transaminases (Moderate)",
        "instanceType": "Condition",
        "description": "ALT or AST levels are greater than 3 times but less than or equal to 5 times the upper limit of normal.",
        "text": "ALT or AST > 3 to <= 5 x ULN"
      },
      {
        "id": "cond_2",
        "name": "Elevated Transaminases (Severe)",
        "instanceType": "Condition",
        "description": "ALT or AST levels are greater than 5 times the upper limit of normal.",
        "text": "ALT or AST > 5 x ULN"
      },
      {
        "id": "cond_3",
        "name": "Hy's Law Criteria",
        "instanceType": "Condition",
        "description": "Bilirubin is elevated above 2x ULN accompanied by ALT elevation above 3x ULN.",
        "text": "Bilirubin > 2 x ULN Accompanied by ALT > 3 x ULN"
      },
      {
        "id": "cond_4",
        "name": "Hemoglobin Decrease",
        "instanceType": "Condition",
        "description": "Hemoglobin is less than or equal to 10 g/dL or has decreased by more than 20% from baseline.",
        "text": "Hemoglobin <= 10 g/dL or > 20% decrease from baseline"
      },
      {
        "id": "cond_5",
        "name": "Platelet Decrease",
        "instanceType": "Condition",
        "description": "Platelets are less than 100,000/mm3 or have decreased by more than 30% from baseline.",
        "text": "Platelets < 100,000/mm3 or > 30% decrease from baseline"
      },
      {
        "id": "cond_6",
        "name": "Neutrophil Decrease",
        "instanceType": "Condition",
        "description": "Neutrophils have decreased by more than 30% from baseline and are below the reference range.",
        "text": "> 30% decrease from baseline and Neutrophils below reference range"
      },
      {
        "id": "cond_7",
        "name": "Neurologic Worsening",
        "instanceType": "Condition",
        "description": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment.",
        "text": "Evidence of neurologic worsening by AEs or by neurologic physical exam assessment"
      },
      {
        "id": "cond_8",
        "name": "Psychiatric Worsening",
        "instanceType": "Condition",
        "description": "Evidence of clinically significant acute psychiatric worsening.",
        "text": "Evidence of clinically significant acute psychiatric worsening which may include but not limited to suicidality, acute depression, or psychosis."
      },
      {
        "id": "cond_9",
        "name": "Safety Review for Titration",
        "instanceType": "Condition",
        "description": "Safety Review Committee (SRC) must review available safety data through Day 23 for each participant before titration.",
        "text": "SRC will review available safety data through Day 23 for each participant."
      },
      {
        "id": "cond_10",
        "name": "Outpatient Period Extension",
        "instanceType": "Condition",
        "description": "The Outpatient Period may be extended with Investigator approval.",
        "text": "The Outpatient Period during Treatment Period 1 may be extended up to an additional 14 days with Investigator approval."
      },
      {
        "id": "cond_11",
        "name": "Maximum Rechallenges",
        "instanceType": "Condition",
        "description": "A maximum of 3 rechallenges will be allowed after dose interruption.",
        "text": "A maximum of 3 rechallenges will be allowed."
      }
    ],
    "conditionAssignments": [],
    "transitionRules": [
      {
        "id": "trans_1",
        "name": "Dose Titration to 30 mg/day",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "On Day 29, participants will be titrated up to 30 mg/day, pending a satisfactory safety review by the SRC of data through Day 23."
      },
      {
        "id": "trans_2",
        "name": "Dose Interruption for Moderate Transaminase Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If ALT or AST > 3 to <= 5 x ULN, temporarily interrupt dosing. Rechallenge at 15 mg QOD when ALT/AST is < 2 x ULN."
      },
      {
        "id": "trans_3",
        "name": "Discontinuation for Severe Transaminase Elevation",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "If ALT or AST > 5 x ULN, discontinue study intervention."
      },
      {
        "id": "trans_4",
        "name": "Dose Reduction for Hematologic Toxicity",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If hemoglobin, platelet, or neutrophil criteria are met, reduce dose to previous dose level or to 15 mg QOD if on 15 mg QD."
      },
      {
        "id": "trans_5",
        "name": "Dose Interruption for Liver Injury",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If Bilirubin > 2x ULN with ALT > 3x ULN, temporarily interrupt dosing. Rechallenge requires approval of the Alexion Medical Monitor."
      },
      {
        "id": "trans_6",
        "name": "Dose Modification for Neurologic or Psychiatric Worsening",
        "instanceType": "TransitionRule",
        "transitionType": "Dose Modification",
        "text": "If neurologic or psychiatric worsening occurs, Investigator and Alexion Medical Monitor will evaluate the need for dose modification (interruption, increase or decrease)."
      },
      {
        "id": "trans_7",
        "name": "Discontinuation for Serious Hypersensitivity",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for a serious hypersensitivity reaction."
      },
      {
        "id": "trans_8",
        "name": "Discontinuation for Severe Infection",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for a severe uncontrolled infection."
      },
      {
        "id": "trans_9",
        "name": "Discontinuation for Pregnancy",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for pregnancy or planned pregnancy."
      },
      {
        "id": "trans_10",
        "name": "Discontinuation for Disallowed Medication",
        "instanceType": "TransitionRule",
        "transitionType": "Discontinuation",
        "text": "Participants must be considered for discontinuation from study intervention for use of disallowed medication."
      }
    ],
    "scheduleTimelineExits": [
      {
        "id": "exit_1",
        "name": "Study Completion",
        "exitType": "Completion",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant is considered to have completed the study if he/she has completed all phases of the study including the last scheduled procedure shown in the Schedule of Activities."
      },
      {
        "id": "exit_2",
        "name": "Participant Withdrawal of Consent",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may withdraw from the study at any time at his/her own request."
      },
      {
        "id": "exit_3",
        "name": "Investigator Discretionary Withdrawal",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant may be withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons."
      },
      {
        "id": "exit_4",
        "name": "Lost to Follow-up",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "A participant will be considered lost to follow-up if he or she repeatedly fails to return for scheduled visits and is unable to be contacted after documented attempts."
      },
      {
        "id": "exit_5",
        "name": "Sponsor Termination of Study",
        "exitType": "Early Termination",
        "instanceType": "ScheduleTimelineExit",
        "description": "Alexion reserves the right to terminate the study at any time for any reason at the sole discretion of Alexion."
      }
    ],
    "scheduledDecisionInstances": [
      {
        "id": "dec_1",
        "name": "Dose Titration Decision",
        "timepointId": "Before Day 29",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Decision point for titrating dose from 15 mg/day to 30 mg/day based on SRC review of safety data.",
        "conditionIds": [
          "cond_9"
        ]
      },
      {
        "id": "dec_2",
        "name": "Dose Modification Decision",
        "timepointId": "Ongoing",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Ongoing decision points to modify, interrupt, or discontinue dosing based on safety monitoring parameters.",
        "conditionIds": [
          "cond_1",
          "cond_2",
          "cond_3",
          "cond_4",
          "cond_5",
          "cond_6",
          "cond_7",
          "cond_8"
        ]
      },
      {
        "id": "dec_3",
        "name": "Outpatient Period Extension Decision",
        "timepointId": "During Outpatient Period",
        "instanceType": "ScheduledDecisionInstance",
        "description": "Adaptive design feature allowing the Investigator to extend the outpatient period by up to 14 days.",
        "conditionIds": [
          "cond_10"
        ]
      }
    ],
    "summary": {
      "timingCount": 19,
      "conditionCount": 11,
      "transitionRuleCount": 10,
      "exitCount": 5
    }
  }
}